Unknown

Dataset Information

0

The Safety of available immunotherapy for the treatment of glioblastoma.


ABSTRACT: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. Current standard of care involves maximal surgical resection combined with adjuvant chemoradiation. Growing support exists for a role of immunotherapy in treating these tumors with the goal of targeted cytotoxicity. Here we review data on the safety for current immunotherapies being tested in GBM. Areas covered: Safety data from published clinical trials, including ongoing clinical trials were reviewed. Immunotherapeutic classes currently under investigation in GBM include various vaccination strategies, adoptive T cell immunotherapy, immune checkpoint blockade, monoclonal antibodies, and cytokine therapies. Trials include children, adolescents, and adults with either primary or recurrent GBM. Expert opinion: Based on the reviewed clinical trials, the current immunotherapies targeting GBM are safe and well-tolerated with minimal toxicities which should be noted. However, the gains in patient survival have been modest. A safe and well-tolerated combinatory immunotherapeutic approach may be essential for optimal efficacy towards GBM.

SUBMITTER: Farber SH 

PROVIDER: S-EPMC5404815 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7826839 | BioStudies
2018-01-01 | S-EPMC6395389 | BioStudies
2014-01-01 | S-EPMC4276952 | BioStudies
2010-01-01 | S-EPMC2809805 | BioStudies
2020-01-01 | S-EPMC7516091 | BioStudies
2016-01-01 | S-EPMC5014608 | BioStudies
2020-01-01 | S-EPMC7594513 | BioStudies
2013-01-01 | S-EPMC3982399 | BioStudies
2017-01-01 | S-EPMC5783695 | BioStudies
2010-01-01 | S-EPMC2786905 | BioStudies